Century Therapeutics, Inc. (IPSC): who owns it and who trades it
As of Nov 16, 2026, IPSC insiders reported 20 open-market sales worth $86.3K and 3 purchases worth $97K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Gregory Russotti (See Remarks), with $40.1K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Century Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns IPSC
99 funds and institutions reported IPSC shares worth $388M at the end of Q2 2026, about 88% of the company. The largest holder is Ra Capital Management, L.P. with 9.8%.
Funds and institutions (13F) 88%Everyone else 12%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 17.75M | 9.84% | $43.5M | No change |
| TCG Crossover Management, LLC | 17.75M | 9.84% | $43.4M | No change |
| Versant Venture Management, LLC | 12.17M | 6.75% | $29.8M | No change |
| Deep Track Capital, LP | 9.46M | 5.25% | $23.2M | -0% |
| Venrock Adviser, LLC | 8.70M | 4.82% | $21.3M | No change |
| Commodore Capital LP | 8.70M | 4.82% | $21.3M | No change |
| Rtw Investments, LP | 8.70M | 4.82% | $21.3M | No change |
| BlackRock, Inc. | 8.09M | 4.49% | $19.8M | +431% |
| Vanguard Capital Management LLC | 5.70M | 3.16% | $14M | +0% |
| Balyasny Asset Management L.P. | 5.52M | 3.06% | $13.5M | +10% |
| Point72 Asset Management, L.P. | 4.98M | 2.76% | $12.2M | -16% |
| Seven Fleet Capital Management LP | 4.35M | 2.41% | $10.7M | +47% |
| Woodline Partners LP | 4.26M | 2.36% | $10.4M | +40% |
| Millennium Management LLC | 4.19M | 2.33% | $10.3M | -10% |
| Trails Edge Capital Partners, LP | 4.13M | 2.29% | $10.1M | +69% |
| Spruce Street Capital LP | 4.06M | 2.25% | $9.9M | No change |
| Adage Capital Partners Gp, L.l.c. | 3.79M | 2.10% | $9.3M | No change |
| Geode Capital Management, LLC | 2.98M | 1.65% | $7.3M | +129% |
| Two Sigma Investments, LP | 2.70M | 1.50% | $6.6M | +14% |
| DAFNA Capital Management LLC | 2.40M | 1.33% | $5.9M | -1% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, IPSC insiders reported $97K of open-market purchases and $86.3K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 3, 2026 | Douglas Carr | Vice president | Sale | 266 | $1.52 | $404 | Form 4 |
| Sep 14, 2026 | Gregory Russotti | See Remarks | Sale | 2,587 | $1.93 | $5K | Form 4 |
| Sep 14, 2026 | Douglas Carr | Vice president | Sale | 1,658 | $1.93 | $3.2K | Form 4 |
| Sep 8, 2026 | Gregory Russotti | See Remarks | Sale | 534 | $2.05 | $1.1K | Form 4 |
| Sep 8, 2026 | Douglas Carr | Vice president | Sale | 254 | $2.05 | $521 | Form 4 |
| Aug 3, 2026 | Douglas Carr | Vice president | Sale | 275 | $1.98 | $544 | Form 4 |
| Jun 12, 2026 | Gregory Russotti | See Remarks | Sale | 2,584 | $2.23 | $5.8K | Form 4 |
| Jun 12, 2026 | Douglas Carr | Vice president | Sale | 1,654 | $2.23 | $3.7K | Form 4 |
| Jun 8, 2026 | Gregory Russotti | See Remarks | Sale | 524 | $2.11 | $1.1K | Form 4 |
| Jun 8, 2026 | Douglas Carr | Vice president | Sale | 249 | $2.11 | $525 | Form 4 |
| May 4, 2026 | Douglas Carr | Vice president | Sale | 264 | $2.34 | $618 | Form 4 |
| Mar 12, 2026 | Douglas Carr | Vice president | Sale | 7,043 | $2.55 | $18K | Form 4 |
| Mar 12, 2026 | Gregory Russotti | See Remarks | Sale | 10,076 | $2.55 | $25.7K | Form 4 |
| Mar 9, 2026 | Gregory Russotti | See Remarks | Sale | 479 | $2.54 | $1.2K | Form 4 |
| Mar 9, 2026 | Douglas Carr | Vice president | Sale | 247 | $2.54 | $627 | Form 4 |
| Feb 3, 2026 | Douglas Carr | Vice president | Sale | 323 | $1.82 | $588 | Form 4 |
| Dec 22, 2025 | Chad Cowan | Chief Scientific Officer | Purchase | 58,060 | $0.85 | $49.4K | Form 4 |
| Dec 12, 2025 | Brent Pfeiffenberger | CEO | Purchase | 52,000 | $0.58 | $30.2K | Form 4 |
| Dec 8, 2025 | Douglas Carr | Vice president | Sale | 257 | $0.53 | $136 | Form 4 |
| Dec 8, 2025 | Gregory Russotti | See Remarks | Sale | 526 | $0.53 | $279 | Form 4 |
| Nov 20, 2025 | Chad Cowan | Chief Scientific Officer | Sale | 5,462 | $0.50 | $2.7K | Form 4 |
| Nov 19, 2025 | Brent Pfeiffenberger | CEO | Purchase | 35,000 | $0.50 | $17.5K | Form 4 |
| Nov 17, 2025 | Brent Pfeiffenberger | CEO | Sale | 32,456 | $0.45 | $14.6K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Brent Pfeiffenberger | President and CEO, Director | $47.7K | $14.6K | Dec 12, 2025 |
| Chad Cowan | Chief Scientific Officer | $49.4K | $2.7K | Dec 22, 2025 |
| Gregory Russotti | See Remarks | – | $40.1K | Sep 14, 2026 |
| Douglas Carr | SVP Finance & Operations | – | $28.8K | Nov 3, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
IPSC short interest
High short interest. 17.7% of IPSC shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 162%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 32.03M IPSC shares were sold short, 17.7% of the shares outstanding, up 9.9% from the report before. At the average daily volume of 1.03M shares, buying them all back would take about 31.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 32.03M | 17.69% | +10% | 1.03M | 31.0 |
| Oct 15, 2026 | 29.13M | 16.09% | -0% | 996,287 | 29.2 |
| Sep 30, 2026 | 29.22M | 16.14% | -0% | 573,911 | 50.9 |
| Sep 15, 2026 | 29.35M | 16.21% | -1% | 373,300 | 78.6 |
| Aug 31, 2026 | 29.53M | 16.31% | +1% | 418,031 | 70.6 |
| Aug 14, 2026 | 29.37M | 16.22% | -1% | 573,918 | 51.2 |
| Jul 31, 2026 | 29.82M | 16.53% | +5% | 732,466 | 40.7 |
| Jul 15, 2026 | 28.38M | 15.74% | +21% | 1.29M | 22.0 |
| Jun 30, 2026 | 23.46M | 13.01% | +52% | 3.00M | 7.8 |
| Jun 15, 2026 | 15.41M | 8.54% | +24% | 975,904 | 15.8 |
| May 29, 2026 | 12.47M | 6.91% | +2% | 921,555 | 13.5 |
| May 15, 2026 | 12.21M | 6.77% | +1% | 653,371 | 18.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Century Therapeutics company events
Century Therapeutics filed 15 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Oct 2, 2026.
- Oct 2, 2026AnnouncementA copy of the slides presented by the Company at EASD is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. Filing
- Sep 9, 2026LeadershipThe Board of Directors of Century Therapeutics, Inc., upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased its size from six to seven directors and appointed Mr. Joseph Truitt as a member of the Board, effective as of September 9, 2026. Filing
- Aug 12, 2026ResultsReleased financial results. Filing
- Jun 16, 2026LeadershipReported a change among its top officers or directors, or their pay. Filing
- Jun 12, 2026VoteReported shareholder vote results. Filing
- Jun 8, 2026AnnouncementCentury Therapeutics, Inc. issued a press release announcing that preclinical data from the Company’s iPSC-derived cell therapy platform was presented at the American Diabetes Association (ADA) 2026 Scientific Sessions being held June 5-8 th in New Orleans, Louisiana. Filing
- May 13, 2026ResultsReleased financial results. Filing
- Mar 26, 2026AnnouncementCentury Therapeutics, Inc. filed with the Securities and Exchange Commission a shelf registration statement on Form S-3 (File No. 333-288616), which became effective on January 9, 2026, and replaced the Company’s previous shelf registration statement on Form S-3 (File No. 333-265975) filed with the… Filing
- Mar 12, 2026ResultsReleased financial results. Filing
- Jan 23, 2026AnnouncementAlso on January 22, 2026, the Company received of a letter from the Nasdaq Stock Market LLC advising the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company to maintain a minimum closing bid price of $1.00 per share and that it is now in… Filing
- Jan 12, 2026AnnouncementShared information with investors. Filing
- Jan 8, 2026AgreementCentury Therapeutics, Inc., entered into a securities purchase agreement with certain institutional accredited investors, pursuant to which the Company agreed to issue and sell to the Investors in a private placement (a) (i) 92,030,595 shares of common stock, par value $0.0001 per share, of the… Filing
- Dec 29, 2025LeadershipCarlo Rizzuto, Ph.D. notified the board of directors of Century Therapeutics, Inc. of his intent to resign from the Board, effective December 18, 2025. Filing
- Dec 12, 2025AnnouncementShared information with investors. Filing
- Dec 9, 2025LeadershipThe Board of Directors of Century Therapeutics, Inc., upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased its size from six to eight directors and appointed Dr. Martin Murphy and Dr. Han Lee as directors of the Board, effective as of December 9, 2025. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Century Therapeutics financials
Famous investors that hold IPSC
4 of the 50 well-known investors we track reported holding IPSC in their latest 13F filing. The largest position is Israel Englander's, worth $10.4M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 6.05M | $10.4M | 0.0% | +44% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 5.11M | $8.7M | 0.0% | +3% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.07M | $1.8M | 0.0% | -15% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 84,660 | $145K | 0.0% | -33% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Century Therapeutics, Inc. (IPSC) stock
Who owns the most IPSC stock?
The largest reported owner of Century Therapeutics, Inc. (IPSC) is Ra Capital Management, L.P., with 9.8% of the company. In total, 99 funds and institutions reported holding IPSC at the end of Q2 2026, together about 88% of the shares. See the largest owners.
Are IPSC insiders buying or selling?
In the last 12 months, IPSC insiders reported 3 open-market purchases worth $97K and 20 sales worth $86.3K. The latest trade was on Nov 3, 2026. See every trade.
What is the short interest in IPSC?
As of Oct 30, 2026, 32.03M IPSC shares were sold short, 17.7% of the shares outstanding, up 9.9% from the report before. At the average daily volume of 1.03M shares, buying them all back would take about 31.0 trading days (days to cover). See the history.
Which famous investors hold IPSC?
4 of the 50 well-known investors we track reported IPSC in their latest 13F filing, including Israel Englander, Steve Cohen, Jim Simons. The largest position is worth $10.4M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.